Engflag

Pregaba M

Quick links to important sections

Pregaba M

Pregaba M_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pregaba M

Property Description
Active Ingredients Pregabalin, Methylcobalamin
Form Capsule
Pharmacological Class Neurological Agent (Anticonvulsant + Vitamin B12 Analogue)
Common Use Targeting Chronic Nerve-Related Discomfort
Origin Synthetic (Pregabalin) and Derived (Methylcobalamin)

What is Pregaba M and Its Pharmacological Class?

Pregaba M is a prescription combination medicine taken orally as a Capsule, classified broadly as a Neurological agent due to its distinct dual action on the nervous system. This agent is structurally defined by its two core Active ingredients: the Anticonvulsant Pregabalin and the neuro-supportive Vitamin B12 Analogue, Methylcobalamin (Mecobalamin). Pregabalin belongs to the gamma-aminobutyric acid (GABA) analogs drug class. The design of this medicine is clinically recognized for addressing nerve-related discomfort by combining a signal modulator with a neuro-nutrient. This formulation provides a differentiating strategy compared to single-ingredient treatments.

The Active Ingredients: Pregabalin and Methylcobalamin

The composition includes the Synthetic compound Pregabalin, which is an alpha2delta Ligand, and Methylcobalamin, which is the biologically active, Derived form of Vitamin B12. Pregabalin performs its primary pharmacological action by binding to the alpha-2-delta (alpha2delta) subunit of voltage-gated calcium channels, which helps to minimize the excessive firing of pain signals. Clinical evidence confirms that this binding action assists in stabilizing overactive neural pathways. Methylcobalamin is the preferred active form of Vitamin B12, specifically included to support nerve health. The use of this active Derived form ensures direct cellular uptake for maintaining nerve fiber integrity and the protective myelin sheath.

General Purpose: Targeting Chronic Nerve-Related Discomfort

The general purpose of Pregaba M is to provide relief from chronic Neuropathic pain by stabilizing damaged nerve signals and supporting long-term nerve health. This combination is typically used in scenarios where patients experience persistent pain, such as burning or tingling sensations, often associated with conditions like diabetic peripheral neuropathy. Pregabalin is intended to modulate the erratic transmission of pain signals, while the Methylcobalamin component promotes the structural health and improved conduction capabilities of the nerve cells. Research broadly supports that dual-therapy approaches combining anticonvulsants with B-vitamins are a medically established strategy for managing peripheral nerve symptoms.

Regulatory References

  1. National Library of Medicine - NIH

What side effects are possible with Pregaba M?

Possible Side Effects and Safety Information

The regulatory safety profile of this medicine reflects the characteristics of its primary active ingredient, Pregabalin. Adverse reactions are classified by frequency as documented in official government sources, such as the EMA Summary of Product Characteristics (SmPC) and FDA Prescribing Information.

Classification of Adverse Reactions

Adverse effects are categorized by the estimated frequency of occurrence:

  • Very Common (ge10%): The most frequently reported effects are dizziness and somnolence (drowsiness).
  • Common (1% to 10%): Commonly observed effects include peripheral edema (swelling), weight gain, blurred vision, dry mouth, and psychiatric effects such as a euphoric mood or confusion.
  • Uncommon (0.1% to 1%): Less frequently reported effects include hypersensitivity reactions, tachycardia (fast heart rate), and suicidal ideation (thoughts of self-harm).

System and Organ Involvement

Side effects are documented across several physiological systems in official labeling:

System-Organ Class Examples of Documented Effects
Nervous System Dizziness, Somnolence, Ataxia (loss of coordination), Tremor
Gastrointestinal System Dry mouth, Constipation, Nausea, Vomiting
Ophthalmological Blurred vision, Diplopia (double vision)
Metabolism & Nutrition Increased appetite, Weight gain

Serious Adverse Reactions and Safety Constraints

Official documents highlight specific serious and life-threatening reactions and safety patterns:

  • Serious Allergic Reactions: Rare but severe reactions classified as Angioedema (severe swelling of the face, mouth, and neck) and Hypersensitivity reactions have been documented.
  • Suicidal Thoughts or Behavior: The primary active ingredient is associated with an increased risk of suicidal thoughts or behavior.
  • Respiratory Depression: The risk of life-threatening respiratory depression is noted, particularly when the medicine is used concurrently with central nervous system (CNS) depressants, such as opioids.
  • Population Safety: Older adults may be at a higher risk for CNS effects like dizziness, and safety is contingent upon appropriate dose adjustment for patients with renal impairment.

Overdose and Emergency Response

Taking more than the prescribed amount of this medicine can lead to an overdose, the manifestations of which are primarily related to central nervous system (CNS) depression from the active ingredient Pregabalin.

Documented Overdose Presentations

Official regulatory documents describe a range of overdose effects, including:

  • CNS Depression: Somnolence (excessive drowsiness), confusion, lethargy, agitation, and disorientation.
  • Severe Outcomes: The potential for progression to severe CNS depression leading to coma, seizures, and respiratory depression (slow or shallow breathing).
  • Cardiovascular: Rare reports of heart block have been noted in the overdose setting.

When to Seek Immediate Medical Help

The regulatory guidance explicitly instructs individuals to seek immediate medical attention for any suspected overdose.

Urgent medical care is specifically required if symptoms involve signs of severe CNS or respiratory depression, such as loss of consciousness, slow breathing, or the occurrence of a seizure.

Management and Considerations

Treatment for overdose is mandated as symptomatic and supportive. Regulatory information confirms that no specific antidote is known for Pregabalin toxicity. However, the drug can be removed from systemic circulation by hemodialysis due to its low molecular weight.

An increased risk of severe toxicity is noted for patients with impaired renal function and those who have taken the medicine with other CNS depressants, increasing the potential for life-threatening outcomes including death.

Therapeutic Uses of Pregaba M

Quick Facts

  • Primary Use: Management of nerve-related discomfort (neuropathic pain).
  • Supportive Use: Helps address symptoms associated with fibromyalgia and certain types of seizures.
  • Specific Conditions: Used to address pain linked to diabetic peripheral neuropathy and postherpetic neuralgia.

Pregaba M is a fixed-dose combination therapy designed to address several conditions, primarily focusing on the management of nerve-related discomfort. This agent is used as a therapy for neuropathic pain associated with specific chronic conditions. These include peripheral neuropathic pain, such as the nerve discomfort linked to diabetic peripheral neuropathy, and postherpetic neuralgia (pain following shingles).

The medication also serves a role in the treatment plan for fibromyalgia, a condition characterized by widespread body discomfort, and may be used as an add-on therapy for certain types of partial-onset seizures in adults. The combined components aim to address nerve function and may support the relief of discomfort and related symptoms.

Eligibility and Restrictions for Use

Who can and cannot use Pregaba M — Official Regulatory Information

The eligibility profile for Pregaba M is defined by a combination of absolute prohibitions, age-based exclusions, and restrictions related to organ function and physiological states, as documented in official regulatory labeling.

Eligibility Scope Regulatory Status
Populations for whom use is allowed Adults (18 years and older).
Populations for whom use is contraindicated Patients with known hypersensitivity to Pregabalin, Methylcobalamin, or any excipients.
Pregnancy and Lactation Contraindicated unless the potential benefit is deemed by a physician to clearly outweigh the risk to the fetus/infant. Women of childbearing potential must use effective contraception during therapy.
Age-related eligibility rules Use in children and adolescents (under 18 years) is not recommended as safety and effectiveness have not been established (Source 1.1).

Condition-Specific Eligibility Restrictions

Use of this medicine is conditional for patients with renal impairment. Because the active substance is eliminated by the kidneys, eligibility for use requires that the dosage be individually adjusted based on the patient’s calculated Creatinine Clearance (Source 2.4). Elderly patients (over 65) may also require dose reduction due to age-related decline in kidney function. Additionally, specific caution is advised for patients with a history of substance abuse due to potential dependence liability, and for elderly patients with cardiovascular compromise (Source 1.4).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Pregaba M is structured around documented pharmacodynamic effects, specific prohibitions, and systemic clearance properties.

The most significant documented concern involves Pharmacodynamic Potentiation. Co-administration with Central Nervous System (CNS) depressants, including Opioids, Benzodiazepines, and Ethanol (alcohol), carries a regulatory warning for additive CNS depression. This interaction increases the risk of severe sedation and respiratory depression, with a noted heightened risk in elderly patients and those with underlying respiratory impairment.

The Methylcobalamin component carries a disease-related restriction: its use is contraindicated in individuals with Leber's Disease due to the risk of severe optic atrophy. Absorption of this component may also be reduced by antacids and certain antibiotics. Furthermore, Folic Acid supplements are documented to potentially mask the hematological symptoms of B 12 deficiency.

Pregabalin is eliminated largely unchanged via renal excretion. Clearance is directly proportional to Creatinine Clearance, a relationship that establishes that reduced renal function results in increased systemic exposure. No clinically significant interactions involving major hepatic CYP enzymes are documented in regulatory labeling. Additionally, co-administration with Glitazones is associated with an increased regulatory note regarding the risk of peripheral edema.

Mechanism of Action

Modulating Neural Signal Hyperexcitability

This agent exerts a complementary influence on the nervous system via two distinct mechanisms. The primary mechanism involves the functional modulation of the alpha2delta subunit of presynaptic Voltage-Gated Calcium Channels (VGCCs), particularly within the central nervous system. Binding to this subunit reduces the voltage-dependent influx of Ca^2+ into the nerve terminal. This action decreases the release of excitatory neurotransmitters, such as glutamate, resulting in the functional suppression of pathological signaling and the modulation of neural circuit activity.

Supporting Nerve Structural Integrity

The second mechanism is centered on neuro-nutritional support provided by the B12 analogue, Methylcobalamin. Functioning as an essential cofactor for the enzyme Methionine Synthase, it plays a role in C1 metabolism. This pathway is vital for the synthesis of phospholipids and structural proteins necessary to maintain the integrity of the myelin sheath and the overall health of the nerve axon. This mechanism supports the structural maintenance of nerve fibers and the integrity of nerve conduction velocity.

Dosage and Administration Information

Pregaba M is a combination prescription medicine intended strictly for oral administration, typically supplied as a hard gelatin capsule. Administration guidelines state that the medicine is generally taken in two (BID) or three (TID) equally divided doses per day. The capsule may be taken with or without food, but it must be swallowed whole and not be crushed, chewed, or broken.

The dosing regimen is based on the Pregabalin component. Treatment typically initiates at 150 mg per day in divided doses. The dose is then adjusted, or titrated, based on individual response, only after a minimum interval of one week following the start of treatment or any previous change. The maximum daily dose for the Pregabalin component is up to 600 mg for certain indications.

Prescribing information mandates procedural constraints for specific populations. Dose adjustment is required for patients with renal impairment, as the Pregabalin component is cleared primarily through the kidneys. Older adults may also require dosage modification due to age-related changes in kidney function. Crucially, when treatment is concluded, the medicine must be tapered gradually over a minimum period of one week to maintain procedural continuity.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pregaba M

This overview describes the types of scientific research that have been conducted for the medicine Pregaba M (Pregabalin + Methylcobalamin), focusing on how the studies were set up and what the data show patterns related to, without giving any individual medical advice or promises about personal outcomes. Studies help show what has been observed so far.

Evidence for Use in Painful Diabetic Peripheral Neuropathy (DPN) and General Nerve Pain

Research has explored whether symptoms change over time in adults with painful nerve damage. For the main active ingredient (Pregabalin), Randomized Controlled Trials (RCTs) were conducted, often compared to placebo. The combination medicine has been primarily evaluated through open-label observational studies and Post-Marketing Surveillance, which explore short-term symptom changes and patient-reported experiences related to physical discomfort.

Evidence for Postherpetic Neuralgia (PHN) and Fibromyalgia

For Postherpetic Neuralgia (pain following shingles) and Fibromyalgia, the evidence base mainly consists of placebo-controlled RCTs and pooled analyses of the monotherapy component (Pregabalin). These studies explored patient-reported outcomes describing perceived discomfort and functional activity levels over defined time intervals. Findings describe patterns observed in these studies compared to the control group in the short term.

What Is Still Uncertain and Research Gaps

Certainty remains low in several areas. A significant gap is the lack of high-quality comparative evidence (such as large, double-blind RCTs) that directly compares the fixed-dose combination to Pregabalin monotherapy. Consequently, the specific contribution of the Methylcobalamin component to pain outcomes is not fully established. Long-term effects are not fully established, as follow-up durations were limited in the core trials. Research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain.

Key Studies & References

  1. Pregabalin Oral Capsule Drug Information (NIH/MedlinePlus)
  2. Vitamin B12 (Cobalamin) Monograph (NIH/MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Pregaba M (FAQ)

Q: What should I do if I miss a dose of Pregaba M?

Official prescribing information on medications containing Pregabalin typically advises consulting the specific guidance provided by a healthcare professional or the product's dosing instructions. Regulatory documents specify the drug should be taken in divided doses daily but generally do not provide a universal, one-size-fits-all rule on how to manage a missed dose, such as whether to take the missed dose or skip it.

Q: Is it safe to take Pregaba M if I have liver problems?

According to official regulatory documents, the Pregabalin component is largely eliminated by the kidneys and is metabolized (broken down) very little by the liver. While this suggests liver function may not significantly impact the drug's clearance, the product labeling does not provide specific dose adjustment guidelines or definitive safety statements for patients with general hepatic (liver) impairment. Any such determination is reserved for a healthcare provider.

Q: Can I stop taking Pregaba M suddenly?

Official drug labels explicitly warn against stopping this medication suddenly. Regulatory documents state that when concluding treatment, the medicine is required to be reduced gradually, or 'tapered,' over a minimum period of one week. Abrupt cessation is associated with potential withdrawal symptoms, which may include dizziness, headache, anxiety, insomnia, and nausea.

How should Pregaba M be stored and disposed of?

How to Store and Dispose of Pregaba M Capsules

The official labeling provides mandatory storage conditions to ensure the integrity of the combination product (Pregabalin and Methylcobalamin).

Storage Requirements

The capsules must be stored in a cool and dry place at a temperature below 30°C (controlled room temperature). The product must be actively protected from light and moisture. To maintain stability, the medication should be kept in its original container until use. As a critical safety requirement, this medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Pregaba M must be disposed of according to local regulatory guidelines. Patients should first attempt to utilize an official drug take-back program. If one is unavailable, the medicine must be prepared for disposal in household trash by mixing the capsules with an undesirable substance (such as used coffee grounds or dirt) and sealing the mixture in a container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pregaba M found in:

A-Z Index: